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ABSTRACT 
Evolution is the study of how variation alters the phenotype and population dynamics 
over time. Population genetics theories fit viral evolution well because of the properties of a 
viral population. Retroviruses are characterized by a high mutation and replication rate, 
which produces a heterogeneous mixture of viral variants commonly referred to as a 
quasispecies. Equine infectious anemia virus (EIAV) infection is a well-studied model for 
retrovirus variation and evolution (32, 33, 34). EIAV infection is characterized by a rapid, 
variable, dynamic disease course. Dynamic features of clinical disease as well as the ability 
of the horse to control the infection makes EIA Van excellent system to study evolution of 
viral quasispecies during progression of clinical disease. Here, we describe analyses of 
genetic data from longitudinal studies of genetic variation in a horse experimentally infected 
with equine infectious anemia virus. These studies include the genes encoding the regulatory 
protein Rev and the surface envelope glycoprotein, SU. Phylogenetic and cluster analyses 
suggested that the population of Rev variants was comprised of two distinct quasispecies that 
co-existed during infection, the populations shifted rapidly during febrile and afebrile periods 
with as little as 10 days between changes in population dominance of populations. In this 
study, we also examined evolution ofEIAV envelope quasispecies during chronic and 
inapparent stages of disease. The data suggests that viral quasispecies in the chronic period 
evolve by random processes while quasispecies in the inapparent period evolve by a 
combination of Darwinian selection and random processes. These results propose that the 
envelope evolves by different processes during different stages of disease. Different 
evolutionary mechanisms during different stages of disease require unique approaches to 
anti-retroviral therapy during different stages of disease. Together, these results suggest 
there are unique host environments and viral population interactions during different stages 
of disease. Multiple quasispecies and varying processes of evolution during persistent 
retrovirus infection challenges the current thinking and has important biological implications 
for control of viral infections. 
1 
CHAPTER!. GENERALINTRODUCTION 
Thesis Organization 
This thesis describes genetic variation of equine infectious anemia virus (EIA V) 
during progression of disease in horses experimentally infected with EIAV. It introduces an 
association in EIAV for concomitant evolution of viral quasispecies during disease 
progression. In the first chapter, an introduction of evolution and viral quasispecies 
establishes a context for the studies undertaken in this thesis . These evolutionary mechanisms 
also allow the virus to adapt quickly to changing environments, including anti-viral therapy. 
Understanding the evolution of virus in vivo is important in the control of viral infections. 
The second chapter is a paper that describes an algorithm designed by Dr. Prasith Baccam for 
grouping genetically similar variants. I helped program the algorithm in C++ to allow a 
variety of researchers to implement the non-hierarchical partitioning approach to discern 
genetic relatedness among viral variants . The third chapter, also a paper, describes an 
examination of rev quasispecies during a chronic EIA V infection. I performed all the 
experiments and analysis described in this chapter. These studies identified two 
complementary quasispecies that fluctuated concomitant with shifts in febrile episodes 
occurring over 90 days. This work supports previous findings of EIA V rev gene in 
longitudinal 3-year study. Chapter 4 is a paper that examines envelope variation during the 
chronic and inapparent stages of disease. I computationally examined EIA V envelope 
variation in a 3-year longitudinal study of a pony with an EIAV. Dr. Brett Sponseller 
provided the sequence data. Clinical data and computational analyses suggest different 
environments in the chronic and inapparent period because the inapparent period is afebrile 
and the immune response matures. Chapter 5 is a general discussion of how the previous 
chapters advance our understanding of evolution of viral quasispecies in vivo. 
Introduction 
Evolution and Adaptation 
Evolution is the study of how variation alters the phenotype and population dynamics 
over time. Evolutionary models make simplified assumptions about interactions between the 
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genes, expressed phenotype, and selection on the phenotype by the environment ( 40). 
Models of evolution allow for probabilistic determinations of mutation, selection, and genetic 
drift on a population leading to a change in the genotypes of the population. 
Models of Evolution 
Evolutionary theories fall into two categories, neutral theory of mutation and 
Darwinian natural selection (50). Darwinian natural selection or adaptive evolution is based 
on deterministic models, which assume a very large population (52). Darwin's theory of 
natural selection states that there is an abundance of nonsynonymous mutations, which are 
deleterious and removed from the population. Adaptive evolution also proposes a small 
amount of advantageous mutations that allow the population to adapt in dynamic 
environments. 
Kimura's neutral mutation theory is governed by stochastic mechanisms that assume 
either a large proportion of neutral mutations or weak selective forces allowing random drift 
to shape the population (50, 64). It also asserts that most of the genetic variability is 
selectively neutral or very nearly neutral (24, 25). The neutral theory proposes that 
advantageous mutations may occur but they are so very rare so they can be discounted from 
calculations of evolution. 
Selection and neutral theory employ different mechanisms to reach the same result. 
Selection proposes a large population that random mechanisms of the neutral theory could 
not evolve. The neutral theory assumes equal substitution rates of nonsynonymous ( dN) and 
synonymous ( dS) codon substitutions, while unequal substitution rates are associated with 
adaptive evolution. These disproportionate substitution rates lead to diversifying or purifying 
selection within the population (62, 63). Purifying selection is an excess of synonymous 
mutations while diversifying selection is a greater amount of nonsysnonymous mutations. 
Assumptions for both theories can be applied to data sets to determine the mode of evolution 
for in vivo populations. Computational methods have been developed to estimate 
evolutionary relationships in genetic populations (27, 28, 29, 31, 47, 51, 57, 62, 63, 64). 
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Characteristics of Virus That Contribute to Quasispecies Theory 
All RNA viruses have similar properties: rapid replication, high mutation rate, and 
large population size. The high mutation rate together with the rapid replication creates a 
large heterogeneous population ofrelated serotypes termed a quasispecies (14, 16). The 
quasispecies is comprised of a central genotype known as a master sequence, which is the 
dominant nucleotide sequence within the population, and a mutant spectra of related 
genotypes (16). The quasispecies is thought of as an infinite population, which is 
overwhelming, but can be described in mathematical terms by the relationship between 
variants of the mutant spectra in precise spatial distances (16). Each sequence that differs 
from its neighbor by one nucleotide should be one unit away from the neighbor and two units 
away from a sequence with two nucleotide differences. Relating all the sequences in this 
way develops a sequence space with each unique sequence occupying a unique point in the 
space. Mutating viruses will expand into the sequence space in an irregular fashion due to 
biological and environmental constraints on virus replication. 
Viruses and Evolutionary Theory 
Viral quasispecies represent complex adaptive systems that have heritable 
components, such as genetic regions, which can respond to environmental changes (52, 19). 
The genetic components of the viral quasispecies confer fitness within different 
environments and allow the population to have a molecular memory over time (52, 19). 
However, this high mutation rate also creates a proportion of deleterious mutations in the 
population, which is in concordance with the natural selection theory (15). These deleterious 
mutations will decrease fitness in a small population of asexual organisms (15). This may 
happen when a population is highly fit or near the fitness peak for the environment that it is 
in: further mutations create a ratchet effect of decreasing fitness, known as Muller's ratchet. 
Recombination can counter the ratchet effect by combining two non-fit individuals to create 
a unique individual of higher fitness (15). Unlike population genetics where selection acts on 
an individual, quasispecies theory states that selection acts on the entire population, which 
promotes an ever-changing viral existence adapting to changing environmental conditions 
(16). 
4 
Computational Tools to Estimate Evolutionary Relationships Within Genetic 
Populations 
The program BioEdit 4.8 .6 is a sequence alignment program that can be used for 
describing genetic relationships among viral sequences (18). Frequency of mutations for 
nucleic acid positions within a gene can be examined. Diversity and divergence can also be 
calculated using nucleotide or amino acid sequences. Diversity is the pair-wise distances of a 
population at a time point, whereas divergence is the pair-wise distances of a population 
compared to a founder sequence. These calculations help define the mechanism of evolution 
as well as changes in the population during different environments. 
The program MEGA 1.1 will describe genetic relationships between sequences by 
phylogenetic analysis (29). To correctly construct genealogical relationships, the program 
MODELTEST can be used to identify the substitution model that fits the data (47). 
MODELTEST does this by resampling the data and testing how it well it fits different 
models of substitution like all substitutions are equally likely or transitions are much more 
likely than transversions. These analyses would help determine the temporal evolution of the 
sequences. 
Calculations of relationships between sequences do not always lead to direct 
conclusions about the evolution of a population. For this reason, direct tests to differentiate 
between stochastic and deterministic mechanisms have been developed. Fixation of 
nonsynonymous ( dN) and synonymous ( dS) mutation rates implies the presence of adaptive 
evolution or neutral mutation. Comparison of these in a ratio of dN/dS = ro has helped 
decipher evolution mechanisms (62, 63) . To test for positive selection, dN/dS pairwise ratios 
can be calculated by using MEGA 2.0 (29). It is generally accepted that dN/dS = ro. An ro > 
1 suggests positive selection while an ro < 1 suggests purifying selection on the population 
and an ro = 1 suggests neutral mutation. The program P AML can be employed to examine 
the role of dN/dS ratios in DNA sequences (62). In this method, three maximum likelihood 
models are used to analyze the data. The first model is the "invariant" model and assumes all 
codons fall into the same category of sites with fixed value of dN/dS. The second "neutral" 
model has two parameters. The first (p 1) assumes that there are neutral sites with ro = 1 and 
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the second parameter (p2) assumes nonsynonymous mutations are deleterious and removed 
from the population so CD= 0. The third model adds a third parameter, positively selected 
sites (p3), which can have an CD> 1. Each model is tested to determine which model best fits 
the data. This examination of specific codon positions can be used with Yang's PAML 
software package ( 42). 
Additional methods examine the neutral mutation hypothesis for any group of 
sequences (57). The Tajima test within the program DnaSP 3.53 uses statistics to examine 
the number of segregating sites and nucleotide distance between two sequences within the 
population analyzed (51 ). The difference between the number of segregating sites and 
average number of nucleotide substitutions is the result of selection ( 59). The test may also 
indicate mutation-selection balance by calculating a negative D value. Assumptions may 
limit the usefuleness of these methods in analyzing some populations, such as viruses. 
Another method with many assumptions for examining the neutral mutation hypothesis is to 
calculate the effective population size. Genetic diversity for each time point can be 
quantified as 8 (2Neµ), estimated using the Metropolis-Hastings Monte Carlo algorithm on 
ultrametric trees of the data using the program FLUCTUATE (27, 28, 31, 64). Small 
population sizes, < 103 would suggest stochastic mechanisms play a major role in evolution 
of the population. Populations with a size between 105 and 103 and would have a 
combination of deterministic and stochastic mechanisms acting on them, while a population 
> 105 would indicate deterministic mechanisms. 
Virus Evolution During Disease Progression 
Characteristics of Retroviruses 
Retroviruses are single stranded RNA viruses. Retroviruses are characterized by 
having a complex genome, which uses a virally encoded error-prone reverse transcriptase to 
make copies of its viral RNA into DNA. These viruses can produce as much as 109 viral 
RNAs a day and mutate approximately 2.3 x 10-4 to 7.0 x 10-5 (20, 23, 43, 46). Reverse 
transcription is critical step in the retrovirus life cycle. The virus must reverse transcribe its 
RNA into double-stranded DNA before being transported to the nucleus of the host cell and 
inserted into the genome. During reverse transcription, there are two strand transfer events 
6 
required to complete replication of the entire genome. Retrovirus reverse transcriptase (RT) 
has evolved nonprocessivity and low template affinity to accommodate the required two 
strand transfer events, which also creates recombination and mutation within the viral 
genome (20, 23, 43). Recombination allows the virus to generate novel viral particles, which 
may create a better-adapted virus. Retroviral RT also lacks 3'-5' exonuclease activity and 
has no ability to proofread reverse transcription, thus providing more mutations (35). The 
large mutation rate of retroviruses as well as a high replication, as high as 109 virus particles 
per day creates a very heterogeneous population of variants termed quasispecies (14, 16). 
These facts allow the virus to adapt very quickly to its environment 
Human Immuodeficiency Virus 1 (HIV-1) 
Human immunodeficiency virus type 1 is a lentivirus in the family of retroviridae. 
HIV-1 exists as quasispecies in vivo, and the genetic diversity within the quasispecies has 
hindered efforts to control and eradicate HIV-1 infection. A number of recent studies have 
examined evolution of HIV-1 in an effort to better understand changes in the viral 
quasispecies during progression of disease. Antigenic variation, the emergence of drug 
resistant variants, and sequestered virus populations contribute to differing disease 
progression profiles in HIV-1 infected patients. The emergence of pathogenic variants (26, 
49) enhancement of virus replication is evident in rapid progressors (8, 13, 41). The 
emergence of T-tropic virus and progression to acquired immune deficiency syndrome 
(AIDS) has been correlated with a decrease in heterogeneity of the viral quasispecies, 
suggesting rapid proliferation of a viral genotype with increased fitness (55). In contrast, the 
presence of attenuated virus has been found in association with slow, nonprogression of 
disease (7, 11 ). These data suggest that the viral phenotype is an important determinant of 
disease progression. 
The rate of evolution of HIV-1 differs in patients with differing disease progression. 
Early in infection, the quasispecies diversity is relatively low, suggesting a transmission 
bottleneck (17, 38, 59, 60, 65, 12, 54). An accumulation of amino acid changes is seen 
throughout infection, (54, 48, 58, 9); however, the rate of accumulation and heterogeneity of 
populations may differ at different stages, or at different rates, of disease progression (41, 13, 
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8). For examples, (5, 26, 49, 54, 55), modest envelope diversity is detected in patients who 
progress rapidly to AIDS, whereas high rates of envelope diversity are characteristic of slow 
progressors (5, 26, 49, 54, 55). It has been suggested that the diversification of the viral 
quasispecies is due to development of a more effective host immune response (54). An 
increase in genetic diversity is also observed during anti-viral therapy. These data indicate 
that changes in the host environment influence evolution of the viral quasispecies (5). 
Elucidating the environmental pressures that shape the viral quasispecies is important for 
long-term control of the viral infection in vivo. 
The emergence of antigenic variants and drug-resistant genotypes are evidence for positive 
Darwinian selection. However, recent studies have proposed that stochastic mechanisms 
drive evolution ofHIV-1 quasispecies. Sala et al. (53) reported a relative linear 
diversification over time, which was evidence that genetic drift and stochastic mechanisms, 
not adaptive immunity, shaped the population. In concert with this data, there have been 
several reports (2, 52, 64) of a small effective population size in the HIV-1 envelope, which 
would allow stochastic processes to more readily affect the population. The low effective 
population size may result from either a low variability in progeny genotypes from a large 
number of infected cells, from proliferation of a homogeneous inoculum, or from variable 
selection at genetically linked sites. Further support for the neutral mutation theory within 
the envelope was the finding of equal substitution rates in the envelope throughout disease 
(31 ). Thus, adaptation within the viral genomes may be a result of both stochastic and 
deterministic. 
Challenges of HIV-1 to Therapy and Vaccine Production 
Production of vaccines and inhibitors of HIV-1 has proven difficult due to high 
variation, sequestered quasispecies, and differing disease progression profiles in patients. 
Drug therapy may increase selective pressure on the virus, results in drug resistant variants. 
These variants then expand and become dominant, making therapy useless. Current 
retroviral therapy used is called highly active anti-retroviral therapy (HAART). HAART is 
an aggressive approach to combat HIV-1 by using a combination of anti-retroviral drugs. 
Due to high mutation rates, drug resistant variants may be present prior to HAART. Ribeiro 
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and Bonhoeffer determined that resistant variants probably pre-exist at low frequencies 
within viral quasispecies because there is a lower probability that mutations would be created 
during HAART (48). This data raises the question that if resistant mutants pre-exist, where 
are they located and how does this effect population dynamics in vivo? Describing the 
population dynamics of these drug resistant variants is important for long-term control of the 
virus. 
Viral Reservoirs May Pose Challenge to Efficient Control of Virus 
Identifying the effects of HAAR T on dynamics of quasispecies has strong 
implications for long-term treatment strategies for control ofretroviruses in vivo (10). It has 
been shown that viral load increase immediately after discontinuation ofHAART (10, 36, 5). 
It is commonly known that there is a reservoir of replication competent virus in resting CD+ 
T cell population. However, this population may or may not be the predominant population 
that rebounds during a cessation ofHAART (5, 36, 10). In fact, rebounding viral populations 
have been found to be distinct from replication-competent, latently infected CD4+ T cells, 
which suggests other regions for rebounding populations (5, 46). It has been proposed that 
rebounding virus may be replicating in isolated regions of the host that is not detectable by 
current methods, and not accessible to current HAART therapies (5, 46). These populations 
may come from different tissue compartments like the brain, gut-associated lymphoid tissues, 
and genital tract (5, 56). Different tissues can provide distinct biological niches for 
alternatively fit viral populations and may serve as the predominant reservoir of viral 
persistence. 
Sequestration in different tissues compartments may allow for the virus to replicate in 
an environment that is not affected by some of the drugs used today. Reservoirs of virus may 
contribute to the rapid re-emergence of virus after cessation ofHAART therapy. Different 
therapies and drug combinations must be used to try and control the ever-present drug 
resistant variants. Multiple faceted drug therapy is one key to control. By requiring the virus 
to be resistant in multiple regions of the genome, we can decrease the probability that the 
virus can adapt. However, studying dynamics of retroviral quasispecies evolution is difficult 
in HIV-1. Studies cannot always define transmission history or earlier quasispecies. 
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Equine Infectious Anemia Virus as a Model for Retrovirus Evolution 
Equine infectious anemia virus (EIA V) infection is a well-studied model for 
lentivirus variation and evolution (32, 33, 34). EIA Vis a member of the lentiviridae 
subfamily of retroviruses and contains a complex genome organization and tropism for cells 
in the macrophage/monocyte lineage, similar to other lentiviruses (4, 37). EIAV infection is 
characterized by a rapid, variable, dynamic disease course. The severity of disease depends 
on the amount of viral replication as the immunological system of the host responds to viral 
replication (3). The variable disease course begins with an acute infection with clinical signs 
including fever, thrombocytopenia, and hemorrhaging (21). The chronic stage of disease is 
typified by cyclic episodes of viremia, fever, depression, edema, and thromocytopenia 
interspersed with brief periods of clinical quiescence. During the inapparent stage of disease, 
the horse is free of clinical signs, yet still infected with the virus. Generally, the horse 
remains inapparent for the rest of its life, but may have relapses of clinical disease. Dynamic 
features of clinical disease as well as the ability of the horse to control the infection makes 
EIA V an excellent system to study evolution of viral quasispecies during progress of clinical 
disease. 
Experimental Evidence for Co-existence of Multiple Quasispecies During 
Persistent Infection 
Quasispecies have been described associated with clinical disease of infected horses 
(1, 34, 32, 33). From a population dynamics perspective, the co-existence of multiple 
populations can have strong effects on evolution. Belshan et al. (1) analyzed genetic data 
from a longitudinal study of genetic variation in a lentivirus regulatory protein, Rev, over the 
course of disease in a horse experimentally infected with equine infectious anemia virus. As 
observed with other lentivirus data, the Rev variants exhibited a quasispecies character. 
Phylogenetic and cluster analyses suggested that the population of Rev variants was 
comprised of two distinct quasi species that co-existed during infection. These two 
quasispecies differed in their pattern of evolution. One population appeared to accumulate 
changes in a linear, time-dependent manner, while the other evolved radially from a common 
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variant. Changes in the population size of these Rev quasispecies coincided with changes in 
clinical disease. Rev variants from each population were assayed for phenotype, and the 
results suggested that the two populations differed in selective advantage. The results of this 
study provide experimental evidence that viral quasispecies may co-exist in distinct 
populations that can evolve independently. These attributes provide the virus great plasticity 
and adaptability to environmental changes within the infected host. 
The literature review presented describes differential accumulation of mutations in 
patients with different disease progression profiles. Identifying the mode of evolution during 
disease progression is important because of the implications in anti-viral therapy and vaccine 
development. Before the virus can be controlled, mechanisms of adaptation to changing host 
environments and mechanisms of immune evasion must be understood. This study uses 
novel computational methods to determine the mechanisms and dynamics of evolution in 
multiple genes of EIAV. In this study, I will describe a novel computer algorithm that 
permitted new insights as to the nature of EIAV Rev quasispecies in vitro. I will also show 
that dissimilar mechanisms of evolution adequately describe differences in EIA V envelope 
populations during chronic and inapparent stages of disease. 
Specific Aims 
We hypothesize that computational tools can enhance our understanding of the mechanisms 
of viral evolution in vivo. To test this hypothesis, we will develop and apply computational 
tools to characterize evolution of viral quasi species throughout disease progression. 
Identifying the dynamics of quasispecies evolution and its effect on antiviral therapy has 
strong implications for long-term treatment strategies for control of retroviruses in vivo (10). 
All of these analyses will expand the knowledge of how the virus is changing to adapt to 
changing host environments and persist without causing disease. 
Specific Aims: 
1. Develop an algorithm to describe evolution of Rev during disease progression in 
Pony 524. (Chapter 1) 
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2. Determine if the dynamics of Rev evolution in Pony 524 are repeatable in another 
horse. (Chapter 2) 
3. Determine if tools can be applied to the envelope GP90 dataset to describe evolution 
of population related to disease progression. (Chapter 3) 
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Abstract 
Motivation: The complexities of genetic data may not be accurately described by any single 
analytical tool. Phylogenetic analysis is often used to study the genetic relationship among 
different sequences. Evolutionary models and assumptions are invoked to reconstruct trees 
that describe the phylogenetic relationship among sequences. Genetic databases are rapidly 
accumulating large amounts of sequences. Newly acquired sequences, which have not yet 
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been characterized, may require preliminary genetic exploration in order to build models 
describing the evolutionary relationship among sequences. There are clustering techniques 
that rely less on models of evolution, and thus may provide nice exploratory tools for 
identifying genetic similarities. Some of the more commonly used clustering methods 
perform better when data can be grouped into mutually exclusive groups. Genetic data from 
viral quasispecies, which consist of closely related variants that differ by small changes, 
however, may best be partitioned by overlapping groups. 
Results: We have developed an intuitive exploratory program, P AQ (partition analysis of 
quasispecies), which utilizes a non-hierarchical technique to partition sequences that are 
genetically similar. PAQ was used to analyze a data set of human immunodeficiency virus 
type 1 (HIV-1) envelope sequences isolated from different regions of the brain and another 
data set consisting of the equine infectious anemia virus (EIA V) regulatory gene rev. 
Analysis of the HIV-1 data set by P AQ was consistent with phylogenetic analysis of the 
same data, and the EIA V rev variants were panitioned into two overlapping groups. P AQ 
provides an additional tool which can be used to glean information from genetic data and can 
be used in conjunction with other tools to study genetic similarities and genetic evolution of 
viral quasispecies. 
Availability: http: //www.vetmed.iastate.edu/units/carplab/P AQ/main.html 
Contact: pbaccam@lanl.gov 
Introduction 
The rapid accumulation of genetic data resulting from high-throughput sequencing 
and the various genome sequencing projects necessitates a variety of computer programs to 
analyze the genetic data. Phylogenetic programs like PHYLIP (Felsenstein, 1993) and PAUP 
(Swofford, 1999) have been increasingly utilized to analyze the evolutionary relationship 
among genetic sequences. Genetic conversions and recombinations, however, may not be 
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modeled well under the branching assumptions of phylogenetic reconstruction. Progress is 
being made on inferring genetic relationships when recombination has occurred. Some 
examples of these methods include spectral analysis (Charleston, 1998), split decomposition 
(Dopazo et al., 1993), and median networks (Guenoche, 1986). Another method of finding 
similarity among sequences is to perform ordination analyses, which attempt to describe the 
multidimensional information in low dimensions. Examples of these methods include 
principal components analysis (PCA) (Mardia et al., 1979), principal coordinates analysis 
(PCOORD) (Gower, 1966, Higgins, 1992), and multivariate statistical sequence analysis (van 
Heel, 1991). The algorithms used to reduce the dimensionality of the data set may, however, 
be non-intuitive to some users, and the results of the analysis may likewise be non-intuitive. 
The program described here, Partition Analysis of Quasispecies (P AQ), is an intuitive 
tool that allows the user to explore genetic data and identify natural groupings of sequences 
that are most similar. The program's intuitive nature comes from the fact that it does not 
assume complex models of evolution like some of the methods mentioned previously. The 
number of clustering techniques currently available is large, but the number of clustering 
programs for analyzing sequence data seems to be limited. Hierarchical methods of 
clustering are the most popular, partly because the output is a dendogram which illustrates 
the clusters. Of the methods that group by hierarchical techniques, the unweighted pair-group 
method using arithmetic averages (UPGMA) method (Lance and Williams, 1966) is one of 
the most widely used. Other hierarchical techniques include single linkage (SLINK) (Sneath, 
1957), complete linkage (CLINK) (Johnson, 1967), and Ward' s method (Ward, 1963). These 
hierarchical methods all belong to the category of agglomerative methods, since each 
element begins within a cluster and the number of clusters is reduced by merging one cluster 
to another cluster. The agglomerative methods merge data together to form clusters which 
grow larger in a process termed "chaining". This chaining process can identify mutually 
exclusive clusters but may have difficulty with overlapping clusters. 
While P AQ shares common features with other clustering methods, its main 
differences are its non-hierarchical clustering algorithm and the fact that P AQ allows for 
overlapping clusters. Unlike the dendogram output of hierarchical methods, PAQ outputs 
partitions, or groups, of genetically similar sequences. The algorithm utilized by P AQ to 
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identify the partitions is similar to the algorithm of K-means (MacQueen, 1965), which is the 
only notable non-hierarchical clustering method. The method of K-means requires that the 
user specify the desired number of partitions prior to cluster analysis. PAQ differs from K-
means, however, by presenting the potential groups and allows the user to determine the most 
appropriate partitions. The main difference between PAQ and K-means is the fact that PAQ 
allows for overlapping groups while K-means forces sequences into mutually exclusive 
groups. While P AQ can be used to analyze many types of sequence data, it was designed 
specifically to analyze viral sequence data. Viruses exist as a heterogeneous population of 
closely related variants, commonly referred to as a quasispecies (Domingo et al., 1996, 
Eigen, 1993, Holland et al., 1992), and thus may not be grouped appropriately by mutually 
exclusive clusters. P AQ is designed to group sequences by using spherical clusters which are 
defined by a radius parameter. This program is not meant to replace phylogenetic analysis or 
the other methods mentioned above, but it offers an alternative exploratory tool for 
investigating groupings of genetically similar quasispecies sequences. 
Systems and methods 
PAQ was written in ANSI C++ and can be compiled and operated on Macintosh, PC, 
and UNIX platforms. The input file should consist of aligned nucleotide or amino acid 
variants. The most basic measure of genetic distance, nucleotide or amino acid change 
(referred to as genetic change hereafter), was used to define the distance between all 
sequences. After the input file is opened, the user has the option to consider or ignore gap 
positions in the distance calculations. A genetic distance matrix is created, where entries 
represent the number of genetic differences between all pairwise sequences summed across 
the entire sequence, also known as a Hamming distance. After all the pairwise sequence 
distances are calculated, the distances are sorted. A gap in the list of sorted distances may 
indicate the presence of distinct, non-overlapping groups. The program identifies the largest 
such region, which may serve as a good radius value to begin searching for groups. The 
remainder of the program is menu-driven and offers the following options: 
1. Display the genetic distance matrix 
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2. Display the groups for a range of radius values 
3. Display the groups for a single radius value 
4. Search a group for sub-groups 
5. Display a rearranged genetic distance matrix 
6. Display all potential group s for a single radius value 
7. Display the average distance from all centers in a range ofradius values 
8. Display all genetic distance from a single sequence 
9. Display the genetic distance between two sequences 
Algorithm 
The basic assumption of the program is that sequences separated by the fewest 
genetic differences are more similar and should thus group together. A radius is selected by 
the user, and each sequence is used as a center to define spherical groups. From all the 
potential groups centered around each sequence, options 2-5 utilize an algorithm which 
automatically identifies all distinct groups (groups containing more than one variant and not 
a subset of other groups). The center genotype of each group is the sequence that is most 
representative of all variants within the group. The first distinct group is the group that 
contains the most variants within it. If more than one group contains the same number of 
variants, then the group that is the most "compact" is chosen. Compactness is characterized 
by having more variants surrounding the center rather than near the boundaries of the group. 
Computationally, the most compact group minimizes the average distance between the center 
and all other variants within the group (neighbors), which is given by the following equation: 
n 
av .dist. = (1/n) L(D;c)2 ( equation 1) 
i= l 
where n is the number of neighbors within the group with center variant c, and Die is the 
genetic distance between variants i and c. Subsequent distinct groups are found in the same 
manner as the first distinct group. 
The second and third menu options utilize the automatic algorithm described above 
and outputs the distinct groups, the center genotype and its neighbors, the variants that 
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belong to more than one group, and the variants that were not contained within any distinct 
groups. The fourth menu option searches for sub-groups within the distinct groups. After an 
initial radius is chosen and the distinct groups are displayed, the user can select a group and 
input a smaller radius to search for sub-groups. The rearranged genetic distance matrix, menu 
option 5, can be a useful tool to search for groups and sub-groups. Using a user-defined 
radius value, the genetic distance matrix is rearranged so that sequences partitioned together 
are grouped together in the new distance matrix. The result is a symmetric matrix with small 
distances around the matrix diagonal and larger distances elsewhere (Figure 1 ). 
In the final analysis of sequence grouping, there may be multiple groups with 
different radius values. Menu options 6-9 offer the user additional information that aids in 
defining the most representative groups. For example, option 6 displays all the potential 
groups rather than the algorithm-derived final groups. Information concerning the average 
distance between the center genotype and all its neighbors can be obtained with menu option 
7. The change in average distances may help to define appropriate radius values for different 
groups. Menu options 8 and 9 provide information concerning distances between specific 
sequences. 
Pseudocode 
input.filename (includes numseq, numsites) 
choose to consider gaps in calculating sequence distances 
calculate Hamming distance between all pairwise sequence comparisons 
( store in distmatrix) 
sort the genetic distances 
output largest region of genetic distance not present in sorted list 
menu: 
1) display the genetic distance matrix 
output distmatrix 
2) display the groups for a range of radius values 
input rmin and rmax 
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for r = rmin, rmax (radius of group) 
for c = 1, numseq ( center of group) 
identify variants within r of c 
for all centers and all radius values, store the number of variants within r of c and the 
average distance of all variants within r of c ( eqn. 1) 
for r = rmin, rmax (radius of group) 
for c = 1, numseq ( center of group) 
identify distinct groups as those with the most variants within r of c (if 
multiple groups have the same number of variants, then choose the 
group with the smallest average distance of all variants within r of 
c ); distinct groups are not subsets of other groups 
for r = rmin, rmax (radius of group) 
output the distinct groups, including the center and all variants within r of the 
center, any variants that belong to more than one group, and all variants not 
contained within any groups 
3) display the groups for a single radius value 
same procedure as menu option (2), with rmin = rmax 
4) search a group for sub-groups 
input r (radius) 
use the procedure for menu option (3) to find distinct groups input clus#, the group to 
search for sub-groups create a new genetic distance matrix for the variants within 
clus# use the procedure for menu option (3) to find distinct sub-groups of clus# 
output the variants that were contained within clus# and the distinct sub-groups 
5) display a rearranged genetic distance matrix 
input r (radius) 
use the procedure for menu option (3) to find distinct groups 
rearrange the genetic distance matrix so that variants within the distinct groups are 
grouped together in the new genetic distance matrix 
output the new genetic distance matrix 
6) display all potential groups for a single radius value 
input r (radius) 
for c = 1, numseq 
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identify and output all variants within r of c 
7) display the average distance for all centers in a range of radius values 
input rmin and rmax 
as in menu option ( 6), identify all potential groups for each radius value 
for r = rmin, rmax 
for c = 1, numseq 
output the average distance of c 
8) display all genetic distance from a single sequence 
input seq 
from the genetic distance matrix, output all genetic distance from seq 
9) display the genetic distance between two sequences 
input seq I 
input seq2 
from the genetic distance matrix, output the distance between seq] and seq2 
Implementation 
P AQ has been tested with several data sets including human immunodeficiency virus 
type 1 (HIV-1) envelope sequences described by Shapshak et al. (Shapshak et al., 1999). The 
HIV-1 sequences consisted of the Vl-V5 domains of the surface envelope gene 
(approximately 1129 bases) isolated from different regions of the brain. Sixty-three 
sequences from this study and another sequence (HIVHXB3), used as the outgroup 
(accession numbers AF125810-AF125874, M14100), were analyzed by PAQ. 
The nucleotide sequences were used to create the genetic distance matrix, ignoring 
gap positions (the analysis when gap positions were considered gave similar findings). After 
sorting the distance between all pairwise sequences comparisons, the program identified that 
no sequences differed by 69-107 nucleotide changes. Using menu option 3 with a radius 
value of 69, three distinct, non-overlapping groups were identified and designated Groups A, 
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B, and C. These groups contained all the sequences except the outgroup sequence. Group A 
contained 41 variants, while Groups B and C contained 13 and 9 variants, respectively. These 
results can be summarized by the rearranged genetic distance matrix, particularly using the 
graphical output of the windows based PC version of the program (Figure 1). Groups A, B, 
and C, identified by P AQ, corresponded to patients 144, 222, and 196, respectively, from 
which the envelope sequences were isolated. 
Using menu option 4 with an initial radius of 69, we searched for possible sub-groups 
present in Groups A, B, and C. In Group A, the program identified that no sequences differed 
by 26 or 27 nucleotide changes. Using a radius value of 26, four distinct, non-overlapping 
sub-groups were found that accounted for all but one variant within Group A. In Group B, a 
radius of 17 (identified by the program) found two distinct sub-groups, where two sequences 
belonged to both sub-groups. Two distinct, non-overlapping sub-groups were identified in 
Group C using a radius of 9 (identified by the program). 
By simply using menu option 3 and the information about regions where no genetic 
distances were detected, three distinct, non-overlapping groups were found that accounted for 
all sequences except the outgroup sequence. Using menu option 4, eight distinct sub-groups 
were found within the three main groups. These 8 sub-groups contained all but two variants, 
and 2 other sequences were shared by 2 of the sub-groups. This broad picture of the groups 
was further refined by utilizing menu options 5-9. For each group, smaller radius values were 
determined to maximize the compactness of the groups. The final result of the group analysis 
show 5 sub-groups in Group A, 3 sub-groups in Group B, and 2 sub-groups in Group C 
(Figure 2). Each of the sub-groups corresponded to sequences that were isolated from the 
same region of the brain. Virus had been isolated from four different regions of the brain. In 
patient 144 (Group A), envelope sequences were amplified from all four regions. In the other 
patients, however, envelope sequences were recovered from only 3 regions in patient 222 
(Group B) and from only 2 regions in patient 196 (Group C). 
The genetic distance between the 3 large groups was approximated by the distance 
separating centers of their respective sub-groups. The genetic distance among Groups A, B, 
and C was greater than 100 nucleotide differences. The large genetic distances separating the 
3 groups further supported the fact that the sequences in this data set had been isolated from 
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3 different patients. The 5 sub-group in Group A had radius values ranging from 7 to 20 
nucleotide differences. In contrast, the range of radius values in the 3 sub-groups of Groups 
B was 4 to 6, and both sub-groups of Group C had a radius value of 3. The genetic distance 
between sub-groups of the major groups was variable and was calculated as the distance 
between the center genotypes of each sub-group. The inter-group distance among sub-groups 
of Group A was generally around 50 nucleotide differences. In Group B, the inter-group 
distance of the sub-groups was around 25 nucleotide differences, and the 2 sub-groups of 
Group C were separated by 36 nucleotides (Figure 2). The genetic diversity within Group A 
was much greater than in the other two groups, as reflected by the large inter-group distances 
and radius values of the Group A sub-groups. This observation suggests that patient 144 
(Group A) had been infected for a longer period relative to the other two patients. Shapshak 
also noted that the genetic divergence within brain regions was higher in patient 144 and 
came to the same conclusion about the relative age of infection in patient 144. Overall, the 
results of our PAQ analysis agreed well with Shapshak's phylogenetic analysis. 
P AQ has also been used to study the viral quasispecies of equine infectious anemia 
virus (EIA V) within a serum sample commonly used to experimentally infect horses. EIA V 
is a lentivirus genetically (Kawakami et al., 1987) and antigenically (Montelaro et al., 1988) 
related to HIV. The data set was comprised of 37 sequences of rev, a regulatory gene 
absolutely required for viral replication. Unlike the HIV data set, these sequences were more 
genetically similar, with only 9 nucleotide differences separating the most distant variants. 
With no obvious radius values to begin the analysis, we used menu option 2 to 
examine the distinct groups defined by radius values from 1 to 9. The group centered around 
variant #1 was the largest distinct group for 6 of the 9 radius values. To determine which 
radius value to further examine, we plotted the number of new neighbors (variants not 
contained in the group defined by smaller radius values) within the group centered around 
variant #1 for the different radius values (Figure 3). A radius value of 3 nucleotide 
differences gave the maximum number of new neighbors, while larger radius values did not 
greatly include more variants. Thus, a radius of 3 nucleotide differences was used to examine 
the rev partitions. 
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Using a radius value of 3 nucleotide differences, variant #1 was the central genotype 
of the major group, which contained 25 neighbors. No other groups were mutually exclusive 
of the group centered around variant #1. To find a minor group, menu option 6 was used to 
display all the potential partitions defined by a radius of 3 nucleotide differences. To identify 
the minor group, all potential partitions were compared with respect to the number (N) and 
proportion (P) of variants within the partition that did not also belong to (overlap with) the 
major group. The partition centered around variant #28 had the largest N value, six, but the 
proportion was P=6/15 (40%). There were 8 other partitions with N=5, and the partition with 
the largest proportion, P=5/8 (62.5%), was centered around variant #16. The only other 
partition with a higher proportion was centered around variant #24, P=2/3 (66%), but the 
partition only had N=2. Thus, the minor group was defined to be the group centered around 
variant #16. A third group was explored, but no groups had a value ofN greater than one. 
Therefore, the EIA V rev variants were characterized by a major group centered around 
variant #1, containing 26 variants, and a minor group centered around variant #16, containing 
8 variants, with 3 variants shared by both groups (Figure 4). 
Discussion and conclusion 
P AQ represents a new tool for cluster analysis. P AQ differs from the majority of 
clustering methods because its non-hierarchical technique uses partitions rather than a 
dendogram to find groups of genetically similar variants. In comparison to the only notable 
non-hierarchical method, K-means, both methods strive to maximize the compactness of the 
distance within groups. The main difference between the two methods is that P AQ allows 
overlapping groups, while K-means forces variants into mutually exclusive groups. This 
difference was designed to handle viral quasispecies data, where variation between sequences 
may be large, as in the HIV example. In the EIA V example, however, the genetic variation in 
that data set was relatively small, an overlapping groups were used to describe the 
quas1spec1es. 
The analysis offered by the P AQ program, as described in the previous section, is an 
intuitive means of grouping genetically similar variants. The genetic distance that separates 
sequences and groups also provides an understandable quantitative tool for researchers 
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studying genetic data. By comparison, P AQ relies on fewer assumptions than phylogenetic 
analyses. Accordingly, P AQ has less power of inference than phylogenetic analyses. 
Implementation of P AQ on the HIV and EIA V data sets, however, exemplifies how the 
partition analyses can find groups of genetically similar sequences that can help researchers 
explore viral quasispecies to better understand the data. The fact that our partition analysis of 
the HIV data and the phylogenetic analysis gave similar results suggests that both analyses 
found some biologically significant results. Furthermore, analysis of the EIA V data by P AQ 
revealed a population structure that was not previously evident. 
There are several layers of complexity involved with genetic data, and no single 
analytical tool can accurately describe the genetic and evolutionary relationships within the 
data. Multiple tools may be necessary to describe the genetic complexity. PAQ is an 
exploratory tool and is not meant to replace other genetic analysis tools, like phylogenetic 
reconstruction and multivariate statistical methods, but it should be used in conjunction with 
other tools to gain insight into how genetic sequences group together and how the variants 
are related. The main strengths of this program are its intuitive nature and its ability to 
explore several types of data, but specifically viral quasispecies data. These strengths may 
best be utilized with newly attained data that is not well-characterized and difficult to model. 
For example, PAQ has been used to analyze a longitudinal study that resulted from the 
experimental infection of a pony with the EIA V inoculum described above. Analysis of the 
partitioned groups present in sequential samples taken post infection can examine their 
dynamic evolution over time (in preparation). Using P AQ to study how viral quasispecies 
exist and evolve may contribute greatly to our overall understanding of viruses. 
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Figure 1. Illustration of the windows based P AQ program. The illustration on the left 
shows the original genetic distance matrix for the HIV-1 brain data, with the darker squares 
indicating large genetic distances. A radius value of 69 was used to group the sequences, and 
an illustration of the rearranged genetic distance matrix is shown on the right. In the 
rearranged distance matrix, the light squares indicate small genetic distances, and the gray 
squares indicate large genetic distances. The rearranged matrix shows three distinct, non-
overlapping groups. 
Figure 2. Groups of HIV-1 env sequences isolated from the brain of infected patients. 
The ten groups, represented by the circles, segregate according to the patients from which the 
sequences were isolated. The genetic distance between groups in different patients(~) was 
much greater than the distance among groups within patients. For each patient, the number of 
variants isolated from the patient is indicated. The numbers within each circle indicates the 
radius of the group (r) and the number of sequences within the group (n) . 
Figure 3. Number of new neighbors in the group centered around variant #1. The range 
of radius values, 0 to 9 nucleotide differences, was used to define the group centered around 
variant #1. For each radius value, the number of new neighbors (variants not contained in the 
group defined by the previous radius value) is plotted. 
Figure 4. The two groups of EIA V rev variants. The size of each group is proportional to 
the number of variants contained within it, and the numbers inside each group represents the 
central genotype. The larger group is centered around variant #1; the miner group is centered 
around variant #16, and the double-hatched region represents the overlap (sharing variants) 
between the two groups. 
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Abstract 
Viruses exist in vivo as a population of related, non-identical genotypes, commonly 
referred to as a quasispecies. Co-existence of multiple populations can have strong effects on 
evolution. Here, we describe analyses of genetic data from a longitudinal study of genetic 
variation in a lentivirus regulatory protein, Rev, over the course of disease in a horse 
experimentally infected with equine infectious anemia virus. Phylogenetic and cluster 
analyses suggested that the population of Rev variants was comprised of two distinct 
quasispecies that co-existed during infection and shifted rapidly during febrile and afebrile 
periods. 
Introduction 
Equine infectious anemia virus (EIA V) is a retrovirus in the subfamily lentiviridae. 
Infection of horses with EIAV is characterized by a highly variable disease course, with three 
distinct stages of clinical disease. The acute stage is characterized by an initial period of high 
titered viremia, fever, and thrombocytopenia that occurs within the first four weeks following 
infection. During the chronic stage of disease, recurrent cycles of viremia, fever, and 
thrombocytopenia occur that decrease in frequency and severity over time and are 
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interspersed with periods of clinical quiescence (9). Absence of clinical signs and 
development of a mature immune response characterize the inapparent period (3). 
Similar to other retroviruses, EIA V has a high mutation rate, high replication rate, and 
recombines readily in vivo. Viral genetic variation is a result of error-prone reverse 
transcriptase (8, 10, 13, 14). These factors result in a heterogeneous mixture of viral variants 
termed quasispecies (4, 5, 7). Increased variation allows viral quasispecies to adapt to 
changing environmental conditions, suggesting that individual genotypes within the mutant 
spectra will be fit in one environment, but not in another (4). 
Variation is thought to play a role in lentivirus persistence and immune evasion. 
Antigenically distinct populations of virus have been associated with cycles ofviremia 
during the chronic stage of disease, suggesting expansion and selection of variants that can 
escape immune pressure (12). One region of high variability in the EIAV genome is the rev 
gene, which is required for replication. Rev is required for production of structural proteins 
such as envelope and transmembrane proteins used to produce new virions. We previously 
undertook a longitudinal study of rev variation in a pony that progressed through all the 
stages of the variable disease course. Pony 524 was infected with virulent strain of Wyoming 
EIA V, EIA V wyo, and multiple time points within each stage of disease were analyzed for 
genetic and phenotypic variation (3, 1, 15). A large amount of variation was seen through 
the disease course. Genotypic and phenotypic variation in rev activity of this variation was 
directly correlated to clinical stage of disease. High Rev activity was associated with acute 
and chronic stages while low rev activity was associated with the inapparent period of 
disease. This suggests the variation in rev may contribute to variation in clinical disease. 
Phylogenetic and cluster analyses indicated that the population of Rev variants was 
comprised of two distinct quasispecies that co-existed during infection (1). These two 
quasispecies populations differed in their pattern of evolution. One population appeared to 
accumulate changes in a linear, time-dependent manner, while the other evolved radially 
from a common variant. Changes in the population size of the Rev quasispecies coincided 
with changes in clinical disease. Rev variants from each population were assayed for 
phenotype, and the results suggested that the two populations differed in selective advantage. 
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These studies provide the first experimental evidence that viral quasispecies may co-exist in 
distinct populations that can evolve independently. 
Here, we extend our previous studies of Rev variation to examine changes in Rev 
quasispecies during the chronic stage ofEIAV infection. Pony 625 was inoculated with a 
pool of sera from pony 524 collected at 878 days post infection ( dpi), which was 124 days 
after the last febrile episode. Sequence and phylogenetic analyses identified two 
complementary quasispecies populations. A rapid transition of dominance in the populations 
was found during a 10-day transition period from one fever cycle to another. The data 
suggests the genetic variation not only associates with distinct chronic and inapparent stages 
of disease, but also associates with intermittent periods of clinical quiescence during the 
chronic period of disease. 
Clinical profile of the acute disease progression in pony 625. Pony 625 was 
infected with sera collected from pony 524 at day 878 days post infection, which was 124 
days after the last febrile episode. Following inoculation, pony 625 experienced multiple 
cycles of fever and thrombocytopenia (Fig. 1). The onset of the first fever cycle occurred at 
12 dpi, and the pony became seropositive at 46 dpi. The horse then progressed into the 
chronic stage of disease, became moribund following a prolonged febrile period initiating at 
78 dpi, and was euthanized at 89 dpi. Viral RNA was isolated from the inoculum and from 
sera samples collected at sequential time points following inoculation, including day 14, 25, 
46, 67, and 77 days post inoculation (dpi). Rev sequences were amplified by RT-PCR, 
cloned, and sequenced according to previous methods (3, 15). Eight - 18 clones were 
sequenced at each time point sampled. Sequence analysis was done using BioEdit, Version 
4.8.6(6), and amino acid variants were identified and aligned (Fig. 2). 
Sequence and phylogenetic analysis shows distinct populations of variants 
throughout disease. The dominant amino acid variant in the inoculum was R93, accounting 
for 37% of the population at this time point. A majority of the remaining variants were 
similar to R93 with a minor population of variants characterized by Rl 03. R93 was again 
dominant at 14 days post inoculation (dpi), and R103 was not detected. R93 remained 
dominant at the next two time points. R103 was detected again at 25 dpi and remained a 
minor population until 46 dpi. At 67 dpi, an intermittent afebrile period, Rl 03 became the 
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dominant variant in the population. R93 was present as a minor variant within the 
population. However, at 77 dpi, the next febrile episode R93 became dominant, with RI 03 
persisting as a minor variant in the population. The sequence analysis suggested two 
populations of variants present during the course of disease. 
The Rev amino acid variants were used to construct phylogenetic trees with the 
neighbor-joining method using MEGA 2.0 (11). The tree was comprised of two distinct 
clades, which were supported well by bootstrapping (Fig 3). Within each clade, the 
sequences were very similar with the largest distance in Clade A being four amino acids, and 
Clade B being three amino acids. However, the distance between the two clades was 
between six and eleven amino acids. This sequence and phylogenetic data supported the 
sequence analysis; both providing evidence for two distinct populations of Rev quasispecies. 
P AQ analysis shows rapid shift in dominant quasispecies during intermittent 
clinical quiescent period. From a population dynamics perspective, the co-existence of 
multiple populations can have strong effects on evolution. To determine the population 
dynamics, we used PAQ beta 1.0, a non-hierarchical partitioning analysis (2). PAQ 
identified two distinct populations in the inoculum with the dominant population was 
characterized by R93 (Group 1) and the minor population characterized by R103 (Group 2) 
(Fig 4) (1). Again, Group 1 was dominant during 14 dpi, however Group 2 was not detected. 
The next two time points were dominated by Group 1 variants with Group 2 as a minor 
population. During an inapparent period between two fever cycles, a minor population of 
Group 2 emerged, as the dominant population while the minor population was Group 1. 
Group 1 was again dominant at 77 dpi. The data shows a rapid transition of dominant 
distinct quasispecies during short, intermittent periods of clinical quiescence. 
We found similar variation in rev during stages of disease, as did Baccam et al. This 
variation grouped into distinct, complementary quasispecies populations that evolved during 
disease. Group 1/Clade A dominated during the acute stage of disease and during the febrile 
episodes in the chronic stage of disease. We saw Group 2/Clade B emerge as the dominant 
population during an intermittent afebrile period with Group 1/Clade A regaining dominance 
10 days later in a febrile episode. The results of this study support previous experimental 
evidence that viral quasispecies may co-exist in vivo as multiple sub-populations that evolve 
41 
independently and possess selective advantages that are distinct. However, we also see the 
rapid emergence of these distinct populations during febrile and afebrile periods. Two 
distinct populations have the ability to adapt very quickly to changing environments as 
Wright suggested in his shifting balance theory as we have seen in these in vivo populations 
(16). 
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Figure Legends 
Figure 1. Fever cycles of Pony 625 during acute and chronic stage of disease. The time 
at which the sequences were sampled is listed below the partitions for the time period. 
Figure 2. Frequency and distribution of Rev sequences obtained from sera of pony 625 
at O, 14, 25, 46, 67, and 77 days post inoculation (DPI). The variant is identified and the 
frequency of each variant is listed next to the name. All variants are compared to R93, the 
dominant variant in the entire population. Similar amino acids are represented by(.) and 
premature stop codons are represented by(*). 
Figure 3. Phylogenetic analysis of all Rev amino acid variants was neighbor-joining 
with p-distance was done using MEGA 2.0. Nucleotide and amino acid trees provided 
similar results. Bootstrapping values show the significance of the two distinct populations. 
Figure 4. Partitioning analysis of Rev nucleotide sequences obtained from sera of pony 
625 experimentally infected with equine infectious anemia virus. The heterogeneity of 
each population represented by a circle is very similar. The size of the circle represents the 
number of clones in the group. 
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Abstract 
Equine infectious anemia virus (EIA V) infection causes a variable disease course 
consisting of chronic and inapparent stages of disease. The cyclic nature of febrile episodes 
during the chronic period in EIA V infection has been associated with the appearance of novel 
envelope variants. Previous studies have focused on characterization envelope variation 
during chronic stages of disease. In this study, we examine viral evolution of quasispecies 
during chronic and inapparent stages of disease under neutral theory and Darwinian natural 
selection models. This study examines a pony experimentally infected with EIA V wyo for a 3-
year period. The pony progressed through all stages of disease providing an opportunity to 
study viral quasispecies evolution during different stages of disease. Distinct viral 
quasispecies were found in the V3 region during different stages of disease suggesting that 
these populations pre-exist and do not evolve during disease progression. Examination of the 
other variable regions found different processes driving evolution during different stages of 
disease. The data suggests that viral quasispecies in the chronic period evolve by random 
processes while quasispecies in the inapparent period evolve by a combination of Darwinian 
selection and random processes. These results propose that different stages of disease evolve 
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by different processes, which requires unique approaches to anti-retroviral therapy during 
different stages of disease. 
Introduction 
RNA viruses have a high replication rate, large population size, short generation time, 
and high mutation rate, which make them excellent for experimental models to study theories 
of population genetics (3 7). In addition, viruses exhibit low epistatic interactions among 
relatively fewer genes as compared to larger genomes of mammalian organisms (37). In 
particular, retroviruses are single stranded RNA viruses with complex genomes that replicate 
through a DNA intermediate. The virally encoded, error-prone reverse transcriptase, 
combined with a high replication rate, and low generation time results in a heterogeneous 
population of variants in vivo termed quasispecies (16, 15, 22, 23, 26, 41, 45, 37, 35). A 
quasispecies is defined as a population of related genotypes comprised of a master sequence, 
which is the dominant nucleotide sequence within the population, and the mutant spectra, 
which is an infinite heterogeneous cloud of variants (16). The variability within this 
population structure allows the quasispecies to selectively expand into the sequence space in 
response to biological and/or environmental constraints. The unit of selection is considered 
to be the entire quasispecies (16), not the individual variants that may be short-lived due to 
movement of the population in a dynamic environment (22). 
Viral quasispecies represent complex adaptive systems that have heritable 
components, such as genetic regions, which can respond to environmental changes by 
deterministic or stochastic mechanisms (27, 49, 43). Deterministic mechanisms, also 
referred to as positive Darwinian selection, can be classified as diversifying or purifying 
selection. Diversifying selection occurs when there is environmental pressure on the 
quasispecies, such as the host immune response or anti-viral therapy, to create new variants 
or escape mutants. Purifying selection eliminates deleterious mutations and enables 
proliferation of the most fit genotype (54). In contrast to deterministic mechanisms, 
stochastic mechanisms, that form the basis for the neutral theory of evolution, can shape viral 
quasispecies by fixation of changes that arise from mutation, migration, and genetic (27, 43). 
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Elucidating mechanisms that shape the evolution of viral quasispecies has important 
implications for design of effective vaccines and anti-retroviral therapies. 
Human immunodeficiency virus type 1 is a lentivirus in the family of retroviridae. 
HIV-1 exists as quasispecies in vivo, and the genetic diversity within the quasispecies has 
hindered efforts to control and eradicate HIV-1 infection. A number of recent studies have 
examined evolution ofHIV-1 in an effort to better understand changes in the viral 
quasispecies during progression of disease. Antigenic variation, the emergence of drug 
resistant variants, and sequestered virus populations contribute to differing disease 
progression profiles in HIV-1 infected patients. The emergence of pathogenic variants (28, 
48), enhancement of virus replication is evident in rapid progressors (8, 14). The emergence 
ofT-tropic virus and progression to acquired immune deficiency syndrome (AIDS) has been 
correlated with a decrease in heterogeneity of the viral quasispecies, suggesting rapid 
proliferation of a viral genotype with increased fitness (54). In contrast, the presence of 
attenuated virus has been found in association with slow, nonprogression of disease (9, 12). 
These data suggest that the viral phenotype is an important determinant of disease 
progression. 
The rate of evolution of HIV-1 differs in patients with differing disease progression. 
Early in infection, the quasispecies diversity is relatively low, suggesting a transmission 
bottleneck (19, 36, 57, 58, 62, 64, 13, 53). An accumulation of amino acid changes is seen 
throughout infection, (53, 47, 56, 11); however, the rate of accumulation and heterogeneity of 
populations may differ at different stages, or at different rates, of disease progression (53, 13, 
17). For examples, (53, 54, 7, 17, 28, 48), modest envelope diversity is detected in patients 
who progress rapidly to AIDS, whereas high rates of envelope diversity are characteristic of 
slow progressors (53, 54, 7, 17, 28, 48). It has been suggested that the diversification of the 
viral quasispecies is due to development of a more effective host immune response (54). An 
increase in genetic diversity is also observed during anti-viral therapy. These data indicate 
that changes in the host environment an influence evolution of the viral quasispecies (7, 17). 
Elucidating the environmental pressures that shape the viral quasispecies is important for 
long-term control of the viral infection in vivo. 
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The emergence of antigenic variants and drug-resistant genotypes are evidence for 
positive Darwinian selection. However, recent studies have proposed that stochastic 
mechanisms drive evolution of HIV-1 quasispecies. Sala et al. reported a relative linear 
diversification in viral genotypes over time, which was evidence that genetic drift and 
stochastic mechanisms, not adaptive immunity, shaped the population (51). In concert with 
this data, there have been several reports (3, 51, 18, 40, 61) of a small effective population 
size in the HIV-1 envelope, which would allow stochastic processes to more readily affect 
the population. The low effective population size may result from either a low variability in 
progeny genotypes from a large number of infected cells, from proliferation of a 
homogeneous inoculum, or from variable selection at genetically linked sites. Further 
support for the neutral mutation theory within the envelope was the finding of equal 
substitution rates in the envelope throughout disease (31 ). Thus, adaptation within the viral 
genomes may be a result of both stochastic and deterministic. 
Equine infectious anemia virus infection is a well-studied model for lentivirus 
variation and evolution (32, 33, 34). EIA Vis a member of the lentiviridae subfamily of 
retroviruses and contains a complex genome organization, and tropism for cells in the 
macrophage/monocyte lineage. EIA V infection is characterized by a rapid, variable, 
dynamic disease course and the severity of disease depends on the amount of viral replication 
(4) . Acute infection includes fever, thrombocytopenia, and hemorrhaging associated with 
high levels of virus replication early after infection (25). The chronic stage of disease is 
typified by cyclic episodes of viremia, fever, depression, edema, and thromocytopenia 
interspersed with brief periods of clinical quiescence. During the inapparent stage of disease, 
the horse is free of clinical signs, yet still infected with the virus. Generally, the horse 
remains inapparent for the rest of its life, but may have relapses of clinical disease. The 
dynamic features of clinical disease as well as the ability of the horse to control the infection 
makes EIAV an excellent system to study the factors important in evolution of viral 
quasispecies during progression of clinical disease. 
The EIA V envelope glycoprotein gp90 has been previously been identified as a 
source of variation forming quasispecies in vivo (23, 33, 63, 5, 4). Viral replication and 
production of heterogeneous populations is ongoing throughout aclinical and clinical disease 
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(32, 33, 34, 63). Localized genetic variation is seen in 8 defined regions of the envelope 
gene encoding the surface glycoprotein (SU), gp90. Most genetic variation in the envelope is 
clustered in two regions, the variable region 5 (V5), also known as the hypervariable region 
(HVR), V5 (62, 33) and the variable region 3 (V3), commonly referred to as the principle-
neutralizing domain (PND) (62). It has been proposed that V3 is under positive selection 
because it is the predominant antibody response (PND) (46, 33, 52, 32, 20, 10, 24). The 
goal of this study is to identify evolutionary mechanisms of SU variation during stages of 
disease. 
Methods 
Experimental Infection. The experimental infection of pony 524 was previously 
reported ( 42, 2). The pony was infected with 103 horse infectious doses of virulent Wyoming 
strain of EIA V (EIA V wyo). Sera and plasma were collected during clinical and subclinical 
infection (Fig. IA) and stored at -80 C until analyzed. 
Virus Neutralization Assay. Assays were performed and reported previously (2). 
Sequence Analysis of Viral Genotypes. Eleven sera samples were analyzed for the 
viral quasispecies present during the disease course; Inoculum, 12, 35, 67, 89, 118,201,289, 
385,437, and 800 days post inoculation (dpi) (Fig. IA). Viral RNA was isolated according 
to previous methods (2). Two regions of the envelope glycoprotein containing variable 
regions V2 - V7 were amplified from viral RNA using RT-PCR, cloned, and sequenced (2). 
Primers were chosen from conserved regions across many isolates to decrease PCR bias (SU-
A: CL 5639' , AAT GCT GGG GTT CCT TCC; CL 6078C', ACA CAG CCT GAT TGG 
ATG. SU-B: CL 5995 ' , CCT AAG GGG TGT AAT GAG; CL 6435C', TGC CTG TCC 
TAT AAC TCC). The 5' region ,SU-A, included variable regions V2 through V4 and the 3' 
region, SU-B, contained variable regions V5 through V7. The regions were referenced as 
SU-A and SU-B for 5' , 3' region respectively (Fig 2). Ten -13 clones were sequenced per 
time point from each region, covering all stages of disease. The program BioEdit 4.8.6 was 
used to align and edit the sequences (21 ). 
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Computational Analysis of Viral Evolution. Diversity and divergence calculations 
were also done using BioEdit 4.8.6 analysis on the amino acid sequences of each region and 
calculating all pair-wise distances using a P AM250 matrix. The diversity of each time point 
is the pair-wise distances of all sequences at each particular time point while divergence is 
the pair-wise distances of each time point as compared to the consensus sequence of the 
inoculum. 
To test for positive selection, dN/dS pairwise ratios were calculated with MEGA 2.0 
(30, 38). It is generally accepted that dN/dS = m. Am> 1 suggests positive selection while a 
m < 1 suggests purifying selection on the population and a m = 1 suggests neutral mutation. 
The program P AML was used to examine the dN/dS ration in each region (39, 59, 60). In 
this method, three maximum likelihood models were used to analyze the data. The first 
model is the "invariant" model and assumes all codons fall into the same category of sites 
with fixed value of dN/dS. The second "neutral" model has two parameters. The first (pl) 
assumes that there are neutral sites with m = 1 and the second parameter (p2) has 
nonsynonymous mutations be deleterious and removed from the population so m = 0. The 
third model adds a third parameter, positively selected sites (p3), which can have am> 1. 
The higher posterior probability was used to determine the model that best fits the data. The 
CODEMLSITES program in the P AML package was used to analyze the data. 
The Tajima test (55) was used to test for selection by using the program DnaSP 3.53 
(49). The Tajima test, examines the neutral mutation hypothesis with the number of 
segregating sites and average number of differences within a population of sequences. When 
using the Tajima test, a D-value greater than one shows positive selection in the population 
while a significant negative value shows purifying selection. A negative D value represents 
mutation-selection balance, which is the balance of mutations recurring in the population 
even though they are rapidly removed because they are deleterious. 
Another method to examine the neutral mutation hypothesis calculates the effective 
population size. Genetic diversity for each time point can be quantified as 8 (2Neµ), 
estimated using the Metropolis-Hastings Monte Carlo algorithm on ultrametric trees of the 
data (program FLUCTUATE, version 1.1), (29). The algorithm constructs evolutionary trees 
with the sequences by swapping branches on the internal nodes of the tree. After finding the 
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best tree, the population can estimate the effective population size by examining the ancestry 
of the population. Effective population size gives a sense of the heterogeneity of the 
population. Population sizes of < 103 would suggest stochastic mechanisms play a major role 
in evolution of the population. Populations with a size between 105 and 103 would have a 
combination of deterministic and stochastic mechanisms acting on them, while a population 
> 105 would be adaptive (18, 61, 51). 
Results 
Clinical Profile of EIA V wy0 -infected Pony 524. The experimental inoculation and 
clinical disease course in Pony 524 was previously described (2). After inoculation, pony 524 
experienced a clinical disease course characterized by recurring fever cycles interspersed 
with afebrile periods ranging from days to months (Fig. IA). The initial acute episode 
included a bi-phasic febrile response and thrombocytopenia from 10 to 22 days post infection 
(DPI), followed by a chronic period of seven recurrent fever episodes which ranged from two 
to six days in length. The last fever episode ended after day 135, and pony 524 remained 
afebrile except for two late fever episodes at days 565 and 799. High virus loads were found 
in the initial fever period at 12 DPI and fell to a nearly undetectable level during the afebrile 
interval at 35 DPI. Virus neutralization assays to EIAVwsu-5, a cell culture derived strain of 
EIAVwyo (44), indicated that broadly reacting neutralizing antibodies appeared after the 
chronic fever cycles subsided (201 DPI) (Fig. lB). Pony 524 maintained elevated 
neutralizing antibody to EIA V wsu-5 throughout the remainder of the experiment. 
Increase in Genetic Variation Seen Over Time. Variation in the envelope gp90 
was observed at each time point, and was largely confined to previously describe variable 
region ofEIAV SU (33, 62) (Fig. 2). The SU-A quasispecies sampled early after infection, 
through 35 DPI, was similar in composition to the inoculum, and the dominant variant in the 
inoculum, SU-Al was still detectable at 67 DPI. As pony 524 progressed to the recurrent 
febrile stage, day 67-118, there were increased numbers of amino acid substitutions in V2-
V7, as well as an insertions/deletion in V3 (clone SU-Al 7). The early afebrile period, 201 
DPl, coincided with the presence of detectable virus neutralizing (VN) antibody (Fig. lB) 
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and was characterized by increased variation in V2-V7 and insertions/deletions in V3. The 
increase in VN antibody titer through 437 DPI was accompanied by large insertions within 
the priniciple-neutralizing domain (PND) in V3 as well as by increased numbers of amino 
acid substitutions in all variable regions. Throughout the afebrile period, new genotypes 
were present at each time point, and we did not detect genotypes that were present in the 
inoculum. During the late febrile period, 800 DPI, there was an expansion of a previously 
detected SU-A genotype, SU-A50, as well as an insertion/deletion in V5. Overall, a 
heterogeneous population characterized each time point with few dominant genotypes. The 
marked increase in variation during the inapparent stage of disease suggested diversifying 
selection in the presence of a maturing host immune response. 
Analysis of the principle-neutralizing domain suggested pre-existence of 
insertion/deletion events. Previous studies have identified insertion/deletions within the V3 
region of EIA V envelope (32, 63). In some cases, these are thought to be due to duplication 
events; in other cases the origin of the insertions is not readily evident. The insertions 
prevalent in this data set were not readily aligned in the context of the entire region 
sequenced. To better characterize these insertion/deletions, they were analyzed separately 
from the other variable regions. The V3 region sequences partitioned into five distinct 
groups. Groupl contained 58 sequences; 51 of these sequences were found only in the acute 
stage of disease. A majority of the group 2 sequences were prevalent in the chronic stage of 
disease. Groups 3 and 4 were prevalent during the inapparent stage of disease. The late 
chronic stage of diseases, again, had one dominant population of insertions. The presence of 
distinct V3 groups was associated with each stage of disease. Analysis shows that there is 
not a temporal evolution of one insertion to another. The insertion populations are wholly 
replaced in each new stage of disease. The data suggests that the insertions do not evolve, 
but pre-exists at a low frequency before it is sampled. Each stage of disease has a different 
selective environment, which favors one distinct population over another and that population 
proliferates. The fact that there are two distinct groups present during the inapparent stage of 
disease implies that there is an environment that is selecting for more diversity during stage 
of disease. 
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Evolutionary Differences in Quasispecies Associated With the Chronic and 
Inapparent Stages of Disease. The emergence ofV3 genotypes and increased genetic 
diversity during inapparent stages of disease was temporally associated with the maturation 
of the host immune response. This suggested that there might be different mechanisms of 
evolution acting in the chronic and inapparent stages of disease. To test this, we grouped the 
genotypes by stage of disease: the chronic period included sequences from 67,89 and 118 
DPI; the inapparent stage included sequences from 289,385, and 437 DPI. This grouping 
eliminated stages with low sample size ( acute and late febrile) as well as transition periods 
(201 DPI). Calculations of divergence and diversity indicated a 2-fold increase from the 
chronic to the inapparent stage of disease in both SU-A and SU-B. This increase could result 
from an accumulation of mutations arising from either stochastic mechanisms or from 
positive selection during the inapparent period. To differentiate between these two 
evolutionary mechanisms, we examined the effective population size, Ne (Fig. 4), which can 
be used to differentiate between deterministic and stochastic mechanisms (3, 61, 18). A 
small effective population size was present in the chronic stage of disease, suggestive of 
stochastic mechanisms of evolution. Although there was an increase in Ne during the 
inapparent stages, it remained below the value generally considered characteristic of adaptive 
evolution (3). These results suggest stochastic mechanisms are predominant during the 
chronic period and a combination of stochastic and deterministic mechanisms are present 
during the inapparent period of disease. To confirm this, we tested for positive selection 
using the Tajima test and dN/dS ratios (55, 38) (Table 2). Both tests demonstrated increased 
positive selection during the inapparent period of disease, although the Tajima test was not 
significant. 
To further examine the regions, a maximum likelihood approach from the program 
CODEML in the P AML package to describe the evolution within the envelope region during 
distinct stages of clinical disease (59, 60). An increased for selection was found in both 
regions of the envelope gene in the inapparent period of disease, as seen by the increase in 
log likelihood values (Table 2). There was also an increase in the proportion of positively 
selected codons during the inapparent period. The pressure of selection on these positively 
selected sites increased by 2 and 3-fold in the SU-A and SU-B regions respectively. There 
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was also an increase of neutral mutations during the inapparent stage of disease. Again, this 
data suggests an increase in adaptive evolution during the inapparent period and purifying 
selection within the chronic period of disease. 
To extend these results; we analyzed data from Leroux et al. using the same methods 
described in this paper, that are publicly available on PUBMED, accession numbers 
AF298703 through AF298762 (32). However, 9 clones were cultured in monocyte-derived 
macrophages for 8 - 14 days. Due to in vitro selection bias, these clones were omitted from 
the analysis. One pony was examined, Pony 567, which had similar clinical disease to Pony 
524. Only fever cycles were sampled in this pony and the conclusions of the authors were 
that immune evasion drove the variation in the variable regions V2 - V8, of the envelope. 
Evolutionary analyses seem to suggest otherwise. Divergence, when plotted on a time scale, 
primarily suggests a linear accumulation of mutations over time, suggesting stochastic 
mechanisms ( data not shown). The effective population size suggests predominance of 
stochastic mechanisms during the chronic periods of disease (Table 3). The Tajima test and 
dN/dS ratios both support the role for neutral mutation theory mechanism shaping the 
population (Table 3). However, both calculations show an increase in selective mechanisms 
approaching the afebrile period at 258 dpi to 640 dpi. However, no time points were sampled 
during the inapparent stage of disease, so the role of selective mechanisms is left to question. 
The next two febrile episodes again show prevalence of stochastic mechanisms in the 
population. In concert with results of Pony 524, the fever cycles of Pony 567 are associated 
with a quasispecies driven by random processes such as genetic drift. This makes a strong 
case for evolutionary differences of quasispecies in inapparent and chronic periods of 
retroviral infection. 
Discussion 
The cyclic nature of febrile episodes in EIA V clinical infection are generally thought 
to be associated with the proliferation of novel viral variants that can escape immune 
detection. Previous studies have limited analysis to characterization of variation within the 
quasispecies during chronic infection. In this study, we study the mechanisms ofEIAV 
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envelope evolution during progression of clinical disease. The study examines a pony, which 
progressed through chronic and inapparent stages of disease when experimentally infected 
with EIA V wyo for a 3-year period. The pony progressed through chronic as well as 
inapparent stages of disease. Thus, this pony provides an opportunity to study viral 
quasispecies evolution. The envelope is a structural protein that is used for viral entry into 
cells. The presence of the envelope on the outside of the virus makes it prevalent to antibody 
response. There are eight variable regions, including variable region 3 (V3) that contains the 
predominant neutralizing antibody response (PND), which are believed to help the virus 
evade the immune system. We found the V3 region segregated into distinct populations, 
which proliferate during different stages of disease, and however, there is no evidence 
evolution of this region during EIA V infection. Analysis of the remaining sequence of the 
envelope indicated that different mechanisms of evolution shape the viral quasisepcies during 
different stages of disease. These differences in mechanisms may be due to maturation of the 
immune response during the inapparent period of disease. 
It is widely accepted that the V3 region is variable because it induces the predominant 
antibody response. This region was found to be confounding when examined within the 
context of the SU-A region due to large insertion/deletion events. The V3 region grouped 
into five distinct groups when analyzed. Each defined stage of disease during EIA V 
infection contained a distinct group of V3 sequences. These results suggest that the V3 
insertions do not evolve, but pre-exist. Distinct groups within each stage of disease suggest 
that each population is fit for a specific stage of disease. The findings support previous 
evidence of complementary quasispecies in vivo ( 1 ). The distinct groups may comprise 
distinct quasispecies in biological niches waiting until the environment favors proliferation. 
Examining the other variable regions showed an increase in heterogeneity of the 
quasispecies observed throughout progression of disease. During the chronic period of 
disease, divergence and effective population size is small. DN/dS ratios suggest slight 
purifying selection, however, the Tajima test is not significant for selection. The data 
suggests the quasispecies in the chronic period evolve by random processes. Conversely, 
during the inapparent period, there is an increase in diversity, effective population size, and 
concomitant maturation of the immune response represented by an increase in virus-
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neutralizing antibody. The Tajima value and dN/dS ratios disagree about the significance of 
selection, but both agree there is an increase in selective pressures during the inapparent 
period. Maximum likelihood analysis also supports an increase in selective pressure with 
increase of dN/dS of positively selected codons 2-3 fold. These results propose different 
processes drive viral evolution in different stages of disease. 
Discrepancies in tests for differential evolutionary processes became evident. This 
may be due to limitations current methods have when analyzing viral quasispecies (3, 11, 29, 
30, 39, 49, 59, 55, 60). These results indicate the need to examine evolution of viral 
quasispecies with multiple tests. 
Recently, there has been controversial evidence on whether stochastic or 
deterministic mechanisms act on in vivo retroviral quasispecies (3, 11, 29, 30, 41 , 49, 59, 55, 
60). The studies have shown different amounts of variation during different stages of 
disease. This study has described evolution of the viral quasispecies during different stages 
of disease. This study has quantified that difference by showing the viral quasispecies in the 
chronic stage of disease is driven by stochastic mechanisms while the inapparent stage of 
disease is affected by both stochastic and positive selection, which may be due to a maturing 
immune response. The conclusions of this study were supported by examination of another 
pony with persistent EIA V infection. These results propose that different stages of disease 
have to be treated uniquely to provide effective therapy to control viral quasispecies in vivo. 
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Figure Legends 
Figure 1. Clinical profile of pony 524 experimentally infected with EIA V wyo• (A) 
Clinical profile of pony 524 including febrile episodes. (B) Virus neutralizing (VN) antibody 
ti tier of pony 524 to EIAVwsu-5. VN titers were determined as described in Belshan et al., 
2001. 
Figure 2. Sequence Alignments of SU-A and SU-B regions within the EIAV envelope. 
(A) shows the sequence alignment of the SU-A region within the envelope glycoprotein gp90 
during a longitudinal study of pony 524 experimentally infected with EIA V wyo· The 
principle neutralizing domain (PND) is contained within this region. (B) shows the sequence 
alignment of the SU-A region within the envelope glycoprotein gp90 during a longitudinal 
study of pony 524 experimentally infected with EIA V wyo• The hypervariable region (HVR) 
is contained within this region. 
Figure 3. Diversity and divergence of populations during different stages of clinical 
disease. (A) Divergence is calculated as all the pair-wise comparisons from one time point 
to the consensus sequence of the inoculum corrected with a PAM250 matrix. The chronic 
period is represented by diagonal bars and the inapparent is filled with black. (B) Diversity 
is calculated by all pair-wise comparisons of the amino acid sequences at one time point 
corrected with a P AM250 matrix. The chronic period is represented by diagonal bars and the 
inapparent is filled with black. 
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Figure 4. The effective population size of each region during the chronic and 
inapparent periods of clinical disease as estimated by the Metropolis-Hastings Monte 
Carlo algorithm. The chronic period is represented by diagonal bars and the inapparent 
period is filled with black. 
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CHAPTER 5. GENERAL CONLUSION 
Conclusion 
Infection of a host with equine infectious anemia virus (EIA V) causes a variable, yet 
defined disease course (7, 2). The acute period characterized by thrombocytopenia, viremia, 
and fever occurs within the first four weeks after infection. The chronic period is 
distinguished by recurrent cycles of fever, thrombocytopenia, and viremia, which decrease in 
severity and frequency over time. Eventually, the horse may enter a clinical inapparent 
period, void of clinical signs, yet persistently infected. The inapparent period is also 
accompanied by broad neutralizing heterologous antibody maturation (1 ). This data suggests 
a different host during different stages of clinical disease. 
EIA V has a high mutation rate due to an error prone reverse transcriptase (8, 5). 
Viruses combine a high mutation rate, titers, and replication rate to create heterogeneous 
populations of quasispecies ( 4, 6). A quasispecies, not individual variants, is the unit of 
selection in viruses (3). The viral quasispecies evolve following theories of population 
genetics. Previous studies have found different amounts variation during different stages of 
disease (9). Viruses are an excellent model to study viral evolution because of rapid 
replication, high mutation, and defined stages of disease. The goal of this study was to 
examine how the genetic variation in EIA V associated with viral persistence. In this study 
we examined the variability in two genes during longitudinal studies of persistent EIA V 
infection to determine processes of evolution during progression of disease. 
Rapid Shift in Dominant Quasispecies During Febrile Cycles 
Previous studies in the lab examined EIA V Rev during a 800-day inoculation of a 
pony. The results suggested two distinct complementary Rev quasispecies present 
throughout infection. These populations had phenotypic activity that correlated to stage of 
disease. In this study, we examined a quasispecies removed from the pony previously under 
study and inoculated into another pony. Data showed that the quasispecies inoculated into 
the pony was similar to the last time sampled from the previous pony. Similar variation in 
Rev during stages of disease was seen as previously described. This variation grouped into 
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distinct, complementary quasispecies populations that evolved during disease. These 
quasispecies were genetically very similar to the populations previously described. Different 
from the previous study, multiple fever cycles along with intermittent afebrile episodes were 
sampled. Computational analysis showed rapid dominance shift in the two populations from 
an intermittent afebrile to another dominant quasispecies during fever just 10 days later. The 
results of this study support previous experimental evidence that viral quasispecies may co-
exist in vivo as multiple sub-populations that evolve independently and possess selective 
advantages that are distinct. Two distinct populations have the ability to adapt very quickly 
to changing environments as Wright suggested in his shifting balance theory as we have seen 
in these in vivo populations (10) . 
Different Evolutionary Processes Associate With Different Stages of Disease 
To further develop the role of quasispecies evolution in viral persistence, we 
examined EIA V envelope from a persistently infected pony. Previous studies have limited 
analysis of the envelope to characterization of variation within the quasispecies during 
persistent infection (10). In this study, we test evolution of viral quasispecies under neutral 
theory and Darwinian natural selection models . This study examines a pony experimentally 
infected with EIA V wyo for a 3-year period. The V3 region grouped into five distinct groups 
when analyzed. Each defined stage of disease during EIA V infection contained a distinct 
group of V3 sequences. These results propose that the V3 insertions do not evolve, but pre-
exist. Distinct groups within each stage of disease suggest that each population is fit for a 
specific stage of disease. The findings support previous evidence of complementary 
quasispecies in vivo (1). The distinct groups may comprise distinct quasispecies in biological 
niches waiting until the environment favors proliferation. 
Examining the other variable regions showed an increase in heterogeneity of the 
quasispecies observed throughout progression of disease. During the chronic period of 
disease, divergence and effective population size is small. DN/dS ratios suggest slight 
purifying selection, however, the Tajima test is not significant for selection. The data 
suggests the quasispecies in the chronic period evolve by random processes. Conversely, 
during the inapparent period, there is an increase in diversity, effective population size, and 
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concomitant maturation of the immune response represented by an increase in virus-
neutralizing antibody. The Tajima value and dN/dS ratios disagree about the significance of 
selection, but both agree there is an increase in selective pressures during the inapparent 
period. Maximum likelihood analysis also supports an increase in selective pressure with 
increase of dN/dS of positively selected codons 2-3 fold. These results propose different 
processes drive viral evolution in different stages of disease. 
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